FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297452685> ?p ?o ?g. }

• W4297452685 endingPage "e46" @default.
• W4297452685 startingPage "e46" @default.
• W4297452685 abstract "Lead Author's Financial Disclosures Nothing to disclose. Study Funding None. Background/Synopsis Common carotid intima-thickness (CIMT) is as a marker of arterial wall injury and arteriosclerosis. Healthy asymptomatic young and middle-aged individuals of the European-ancestry show mean CIMT of 610 + /-110μmmicrometers with a strong linear relation between age and CIMT. In the general population, an annual rate of change in mean common CIMT is estimated at 15μm (95% CI, 12 to 17), with a median standard deviation of 53. Objective/Purpose We sought to compare annual CIMT progression rates in 10 patients with severe hypercholesterolemia treated with lipoprotein apheresis with published annual CIMT progression estimates in age-comparable 1) healthy individuals based on the nomograms, 2) patients with elevated lipoprotein(a), and 3) familial hypercholesterolemia (FH). Methods Patients (mean age 60+/-9 years, 70% female, 80% statin intolerant) were treated with the dextran sulfate adsorption apheresis system for primary and secondary atherosclerotic cardiovascular disease (ASCVD) prevention every two weeks between 2005 and 2020 (mean duration, 10+/-4 years). To minimize intra-individual and inter-individual variability in CIMT assessment we used computerized algorithms with measurements performed by the same sonographer. Results The baseline mean CIMT was 850+/-170μm and maximum CIMT was 1040+/-220um across the age range of 46 to 70 years. The baseline median levels of total cholesterol were 317 (interquartile range (IQR), 262 to 361); LDL-C, 214 (133 to 253); HDL-C, 56 (44 to 68); triglycerides, 170 (121 to 215), lipoprotein(a), 26 (9 to 120), all in mg/dL. Acute effects of lipoprotein apheresis determined as a difference before and immediately after the procedure were estimated as a median of 72+/-8% and 75+/-7% reduction in the LDL-C and lipoprotein(a) levels, respectively. Regular treatment with lipoprotein apheresis resulted in average reduction in the mean CIMT of −40μm (IQR, −50 to 20). An annual CIMT progression rate was associated with the combined percentage reduction in the lipoprotein(a) (P=0.032) and LDL-C levels (P=0.029). Using the Bayesian Estimation Supersedes the t -Test (BEST) method, the annual rate of CIMT progression was compared to those reported in the literature (Table 1). Conclusions Composite CIMT progression rates were slowed with lipoprotein apheresis. In this cohort of high-risk patients with poor statin tolerance, the use of CIMT surveillance was noted to increase compliance with long-term lipid-modifying therapies in the clinical setting. Nothing to disclose." @default.
• W4297452685 created "2022-09-29" @default.
• W4297452685 creator A5001122371 @default.
• W4297452685 creator A5016701722 @default.
• W4297452685 creator A5017217753 @default.
• W4297452685 creator A5041331057 @default.
• W4297452685 creator A5050387718 @default.
• W4297452685 creator A5067296668 @default.
• W4297452685 date "2022-07-01" @default.
• W4297452685 modified "2023-10-18" @default.
• W4297452685 title "Intima-media Thickness Measured at the Common-carotid Artery in Patients Treated with Lipoprotein Apheresis" @default.
• W4297452685 doi "https://doi.org/10.1016/j.jacl.2022.05.022" @default.
• W4297452685 hasPublicationYear "2022" @default.
• W4297452685 type Work @default.
• W4297452685 citedByCount "0" @default.
• W4297452685 crossrefType "journal-article" @default.
• W4297452685 hasAuthorship W4297452685A5001122371 @default.
• W4297452685 hasAuthorship W4297452685A5016701722 @default.
• W4297452685 hasAuthorship W4297452685A5017217753 @default.
• W4297452685 hasAuthorship W4297452685A5041331057 @default.
• W4297452685 hasAuthorship W4297452685A5050387718 @default.
• W4297452685 hasAuthorship W4297452685A5067296668 @default.
• W4297452685 hasConcept C119060515 @default.
• W4297452685 hasConcept C126322002 @default.
• W4297452685 hasConcept C164705383 @default.
• W4297452685 hasConcept C2777910003 @default.
• W4297452685 hasConcept C2778163477 @default.
• W4297452685 hasConcept C2779120738 @default.
• W4297452685 hasConcept C2779339615 @default.
• W4297452685 hasConcept C2908647359 @default.
• W4297452685 hasConcept C2987047532 @default.
• W4297452685 hasConcept C71924100 @default.
• W4297452685 hasConcept C99454951 @default.
• W4297452685 hasConceptScore W4297452685C119060515 @default.
• W4297452685 hasConceptScore W4297452685C126322002 @default.
• W4297452685 hasConceptScore W4297452685C164705383 @default.
• W4297452685 hasConceptScore W4297452685C2777910003 @default.
• W4297452685 hasConceptScore W4297452685C2778163477 @default.
• W4297452685 hasConceptScore W4297452685C2779120738 @default.
• W4297452685 hasConceptScore W4297452685C2779339615 @default.
• W4297452685 hasConceptScore W4297452685C2908647359 @default.
• W4297452685 hasConceptScore W4297452685C2987047532 @default.
• W4297452685 hasConceptScore W4297452685C71924100 @default.
• W4297452685 hasConceptScore W4297452685C99454951 @default.
• W4297452685 hasIssue "3" @default.
• W4297452685 hasLocation W42974526851 @default.
• W4297452685 hasOpenAccess W4297452685 @default.
• W4297452685 hasPrimaryLocation W42974526851 @default.
• W4297452685 hasRelatedWork W1970484759 @default.
• W4297452685 hasRelatedWork W1991129960 @default.
• W4297452685 hasRelatedWork W2072098281 @default.
• W4297452685 hasRelatedWork W2134825011 @default.
• W4297452685 hasRelatedWork W2140339203 @default.
• W4297452685 hasRelatedWork W2146656800 @default.
• W4297452685 hasRelatedWork W2166614723 @default.
• W4297452685 hasRelatedWork W2183331098 @default.
• W4297452685 hasRelatedWork W2888351225 @default.
• W4297452685 hasRelatedWork W2900559475 @default.
• W4297452685 hasVolume "16" @default.
• W4297452685 isParatext "false" @default.
• W4297452685 isRetracted "false" @default.
• W4297452685 workType "article" @default.